THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SAXAGLIPTIN (SAXA) AMONG OLDER INDIVIDUALS LIVING WITH TYPE 2 DIABETES MELLITUS (T2DM) IN CANADA

被引：0
|
作者：
Teschemaker, A. R. [1 ]
Neslusan, C. [1 ]
Sabapathy, S. [2 ]
Yoong, K. [2 ]
Johansen, P. [3 ]
Willis, M. [3 ]
机构：
[1] Janssen Global Serv LLC, Raritan, NJ USA
[2] Janssen Inc, Toronto, ON, Canada
[3] Swedish Inst Hlth Econ, Lund, Sweden
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.365
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB58
引用
收藏
页码：A62 / A63
页数：4
相关论文
共 50 条
  • [1] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
  • [2] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [3] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [4] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [5] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [6] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Thompson, G.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Schroeder, M.
    Girod, I
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [7] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH INADEQUATE CONTROL ON METFORMIN (MET) MONOTHERAPY IN THE UNITED KINGDOM
    Schroeder, M.
    Johansen, P.
    Thompson, G.
    Willis, M.
    Neslusan, C.
    VALUE IN HEALTH, 2014, 17 (07) : A344 - A344
  • [8] COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
    Neslusan, C.
    Teschemaker, A.
    Martin, S.
    Willis, M.
    Johansen, P.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [9] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [10] Genital Mycotic Infections With Canagliflozin (CANA) in Subjects With Type 2 Diabetes Mellitus (T2DM)
    Nyirjesy, Paul
    Sobel, Jack
    Fung, Albert
    Gassmann-Mayer, Cristiana
    Ways, Kirk
    Usiskin, Keith
    DIABETES, 2013, 62 : A276 - A276
12345